Skip to main content
SpringerLink
Log in

Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

This study was undertaken to evaluate the ocular hypotensive efficacy of brimonidine Purite® 0.15% (Alphagan® P 0.15%; Allergan, Inc., Irvine, Calif) given as adjunctive therapy with latanoprost 0.005% (Xalatan®; Pfizer Inc., New York, NY) to patients with open-angle glaucoma or ocular hypertension. In this multicenter, open-label, prospective evaluation, the intraocular pressure (IOP) of the 43 enrolled patients was ≥18 mm Hg after at least 6 wk of latanoprost monotherapy. The primary outcome measure was IOP at peak drug effect (10 am, or approximately 2 h after the morning dose of brimonidine 0.15%). IOP at trough drug effect (8 am, or approximately 12 h after the evening dose of brimonidine) was also measured. Baseline IOP was 21.9 (±2.3) mm Hg. After 1 mo of treatment, additional mean IOP reductions from latanoprost-treated baseline values were 5.8 mm Hg (26%) at peak drug effect (P < .001) and 3.3 mm Hg (15%) at trough (P < .001). At the month 2 visit, additional mean IOP reductions from latanoprost-treated baseline values were 5.1 mm Hg (23%) at peak drug effect (P < .001) and 2.0 mm Hg (9%) at trough (P=.002). Brimonidine Purite 0.15% provided statistically significant additional reductions in IOP from latanoprost-Transmission and reproduction of this material in whole or part without prior written approval are prohibited. treated baseline values. These findings suggest that brimonidine Purite 0.15% is an efficacious adjunctive therapy in patients given latanoprost who require additional lowering of IOP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Similar content being viewed by others

References

  1. Quigley HA. Number of people with glaucoma worldwide.Br J Ophthalmol. 1996; 80: 389–393.

    Article  PubMed  CAS  Google Scholar 

  2. Friedman DS, Wolfs RC, O’Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States.Arch Ophthalmol. 2004; 122: 532–538.

    Article  PubMed  Google Scholar 

  3. Research to Prevent Blindness. Glaucoma. Available at: http://www.rpbusa.org/glaucoma.php. Accessed August 8, 2006.

  4. Lichter PR, Musch DC, Gillespie BW, et al for the CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery.Ophthalmology. 2001; 108: 1943–1953.

    Article  PubMed  CAS  Google Scholar 

  5. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.Arch Ophthalmol. 2002; 120: 701–713.

    PubMed  Google Scholar 

  6. Allergan, Incorporated. Alphagan® P prescribing information. Available at: http://www.allergan. com/download/ALPHGANP_PI.pdf. Accessed August 7, 2006.

  7. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.J Glaucoma. 2002; 11: 119–126.

    Article  PubMed  Google Scholar 

  8. Simmons ST, Earl ML, for the Alphagan/Xalatan Study Group. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.Ophthalmology. 2002; 109: 307–315.

    Article  PubMed  Google Scholar 

  9. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.J Glaucoma. 2001; 10: 220–226.

    Article  PubMed  CAS  Google Scholar 

  10. Zabriskie NA, Ahmed IK, Cantor LB, et al. Safety and efficacy of combination therapy with brimonidine 0.2% and latanoprost 0.005% versus fixed timolol 0.5%/dorzolamide 2% in patients with glaucoma or ocular hypertension.Invest Ophthalmol Vis Sci. 2000; 41(suppl 4): S833.

    Google Scholar 

  11. Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.Clin Ther. 2000; 22: 103–111.

    Article  PubMed  CAS  Google Scholar 

  12. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.Arch Ophthalmol. 1997; 115: 847–852.

    PubMed  CAS  Google Scholar 

  13. Leske ME, Heijl A, Hussein M, et al, for the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial.Arch Ophthalmol. 2003; 121: 48–56.

    PubMed  Google Scholar 

  14. Allergan, Inc. Alphagan® P FAQs. Available at: http://www.alphaganp.com/ALPHGANP.pdf. Accessed August 7, 2006.

  15. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.Ophthalmology. 1993; 100: 1297–1304.

    PubMed  CAS  Google Scholar 

  16. Goldberg I. Drugs for glaucoma.Aust Prescr. 2002; 25: 142–146.

    Google Scholar 

  17. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.Am J Ophthalmol. 1999; 128: 8–14.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charlotte, North Carolina

    Thomas Mundorf MD (Private Practice)

  2. UPMC Eye Center Department of Ophthalmology, University of Pittsburgh School of Medicine, 203 Lothrop Street, Suite 820, 15213, Pittsburgh, PA

    Robert J. Noecker MD (Vice Chair)

  3. IMEDS, Inc., Riverside, California

    Melissa Earl MPH

Authors
  1. Thomas Mundorf MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J. Noecker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melissa Earl MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Noecker MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mundorf, T., Noecker, R.J. & Earl, M. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. Adv Therapy 24, 302–309 (2007). https://doi.org/10.1007/BF02849898

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02849898

Keywords

Search

Navigation